

## **Bulletin from the extraordinary general meeting in CELLINK AB (publ)**

At the extraordinary general meeting in CELLINK AB (publ), held on December 17, 2020, the following resolutions were passed.

- The extraordinary general meeting resolved, in accordance with the nomination committee's proposal, to elect Aristotelis Nastos as a new member of the board of directors of Cellink. The board of directors therefore consists of Carsten Browall (Chairman), Bengt Sjöholm, Christian Wildmoser, Erik Gatenholm, Helena Skåntorp, Ingela Hallberg and Aristotelis Nastos, all for the period until the end of the next annual general meeting.
- The extraordinary general meeting resolved, in accordance with the proposal by the board of directors, to authorise the board of directors, for the period until the end of the next annual general meeting, at one or several occasions and with or without deviation from the shareholders' preferential rights, to resolve on a new issue of shares of series B. The authorisation may be utilised for new issues of shares of series B, which may be made with provisions regarding contribution in cash, in kind or through set-off corresponding to a dilution of not more than 10 per cent of the registered share capital in the company at the time of the issue resolution. In addition, in connection with acquisition of businesses, companies or rights, the board shall be able to resolve on issues in kind or through set-off corresponding to a further maximum 10 per cent of the registered share capital in the company at the time of the issue resolution. Thus, the total authorisation, corresponding to a maximum of 20 per cent, requires that at least 10 per cent be used for issues in kind or through set-off made in connection with the acquisition of businesses, companies or rights. The subscription price shall be determined on market terms and conditions.

Deviations from shareholders' preferential rights should only be possible in connection with acquisitions of operations, companies, participations in companies and other rights associated therewith or for the company's continued expansion. If the board of directors resolves on an issue with deviation from the shareholders' preferential rights, the rationale should be that the board quickly and efficiently may issue shares in the company to be utilised as means of in-kind payment or the right to offset debt or to in a flexible and cost-efficient manner raise capital to use as means of payment.

The new authorisation replaces the existing authorisation from the annual general meeting on 18 December 2019.

Approximately 67.6 per cent of the votes were represented at the extraordinary general meeting.

For further information, please contact:

**Erik Gatenholm, CEO**

Phone (Sweden): +46 73 267 00 00

Phone (US): +1 (650) 515 5566

Email: [eg@cellink.com](mailto:eg@cellink.com)

**Gusten Danielsson, CFO**

Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (857) 332 2138

Email: [gd@cellink.com](mailto:gd@cellink.com)

This information was submitted for publication, through the agency of the contact persons set out above, on December 17, 2020 at 20:30 CET.

**About CELLINK**

Founded in 2016, CELLINK is a global life-science company that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, analysis, and liquid handling and bioprocessing, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK's products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 200 publications. CELLINK is creating the future of medicine.

Visit [cellink.com](http://cellink.com) to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.